The EACR’s ‘Highlights in Cancer Research’ is a regular summary of the most interesting and impactful recent papers in cancer research, curated by the Board of the European Association for Cancer Research (EACR).
The list below appears in no particular order, and the summary information has been provided by the authors unless otherwise indicated.
Use the dropdown menu or ‘Previous’ and ‘Next’ buttons to navigate the list.
5. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
Fidelle, M., Rauber, C., Alves Costa Silva, C. et al. Science. 380 (6649): eabo2296 (2023).
doi: 10.1126/science.abo2296.
Summary of the findings
In Fidelle, Rauber & Alves Costa et al., we demonstrate a mechanistic link between antibiotics (ABX) and compromised cancer treatment effectiveness using programmed cell death protein 1 (PD-1) blockade. The study reveals that ABX can suppress the immune system by downregulating a gut-specific cell adhesion molecule called “mucosal addressin cell adhesion molecule 1 (MAdCAM-1)” in the ileum, leading to the emigration of suppressive immune cells away from the intestine into distant tumours, where they inhibit PD-1 antibody efficacy. These immunosuppressive T cells were characterized by a Treg/Th17 phenotype. Enterocloster species, which thrive after ABX use, were found responsible for triggering MAdCAM-1 suppression and migration of these suppressive immune cells. Faecal microbiota transplantation aimed at restoring gut microbiota eubiosis or interleukin-17A neutralization was shown to prevent ABX-induced immunosuppression. In cancer patients treated with PD-1 blockade, low serum levels of soluble MAdCAM-1 were associated with poor clinical outcomes (compared with normal levels) in lung, kidney, and bladder cancer patients, supporting the impact of the MAdCAM-1-α4β7 axis in cancer immunosurveillance.
The figure was kindly created by Stefan Homentcovschi.
Future impact
These findings shed light on the complex interactions between gut bacteria, antibiotics, and cancer immunotherapy. Serum soluble MAdCAM holds promise as a potential biomarker to identify patients at high risk of gut microbiota dysbiosis and PD-1 blockade treatment failure, paving the way to stratify patients for microbiota-centered interventions.
EACR member Amel Aziba has now completed her EACR-Molecular Oncology Editorial Fellowship, funding that is awarded to enable a talented cancer researcher to gain knowledge and...
Pilar Salamanca Jiménez is a PhD Candidate at the Bellvitge Biomedical Research Institute (IDIBELL), at the University of Barcelona, Spain, who received an EACR Travel Fellowship...
Patrycja Fryzik is a PhD student at the Princess Maxima Center for Pediatric Oncology, The Netherlands, who received an EACR Travel Fellowship to visit and work...
About Us
The Cancer Researcher is an online magazine for the cancer research community from the European Association for Cancer Research.
The EACR, a registered charity, is a global community for those working and studying in cancer research. Our mission is “The advancement of cancer research for the public benefit: from basic research to prevention, treatment and care.”
Summary of the findings
Summary of the findings
